🚀 VC round data is live in beta, check it out!
Heidelberg Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Heidelberg Pharma and similar public comparables like Alpha Cognition, Kotra Industries, vTv Therapeutics, Innate Pharma and more.
Heidelberg Pharma Overview
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Founded
1997
HQ
Employees
116
Website
Sectors
Financials (FY)
EV
$134M
Heidelberg Pharma Financials
Heidelberg Pharma reported last fiscal year revenue of $2M and negative EBITDA of ($45M).
In the same fiscal year, Heidelberg Pharma generated $1M in gross profit, ($45M) in EBITDA losses, and had net loss of ($50M).
Revenue (LTM)
Heidelberg Pharma P&L
In the most recent fiscal year, Heidelberg Pharma reported revenue of $2M and EBITDA of ($45M).
Heidelberg Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 81% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($45M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2635%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (3228%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($50M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (2901%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Heidelberg Pharma Stock Performance
Heidelberg Pharma has current market cap of $151M, and enterprise value of $134M.
Market Cap Evolution
Heidelberg Pharma's stock price is $3.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $134M | $151M | -1.7% | XXX | XXX | XXX | $-1.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHeidelberg Pharma Valuation Multiples
Heidelberg Pharma trades at 77.8x EV/Revenue multiple, and (3.0x) EV/EBITDA.
EV / Revenue (LTM)
Heidelberg Pharma Financial Valuation Multiples
As of April 18, 2026, Heidelberg Pharma has market cap of $151M and EV of $134M.
Equity research analysts estimate Heidelberg Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Heidelberg Pharma has a P/E ratio of (3.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $151M | XXX | $151M | XXX | XXX | XXX |
| EV (current) | $134M | XXX | $134M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 77.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.0x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (2.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 95.6x | XXX | XXX | XXX |
| P/E | — | XXX | (3.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Heidelberg Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Heidelberg Pharma Margins & Growth Rates
Heidelberg Pharma's revenue in the last fiscal year declined by (77%).
Heidelberg Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
Heidelberg Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (77%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2635%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 92% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 522% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2661% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 3309% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Heidelberg Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Heidelberg Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| Kotra Industries | XXX | XXX | XXX | XXX | XXX | XXX |
| vTv Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Innate Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Abionyx Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heidelberg Pharma M&A Activity
Heidelberg Pharma acquired XXX companies to date.
Last acquisition by Heidelberg Pharma was on XXXXXXXX, XXXXX. Heidelberg Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Heidelberg Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHeidelberg Pharma Investment Activity
Heidelberg Pharma invested in XXX companies to date.
Heidelberg Pharma made its latest investment on XXXXXXXX, XXXXX. Heidelberg Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Heidelberg Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Heidelberg Pharma
| When was Heidelberg Pharma founded? | Heidelberg Pharma was founded in 1997. |
| Where is Heidelberg Pharma headquartered? | Heidelberg Pharma is headquartered in Germany. |
| How many employees does Heidelberg Pharma have? | As of today, Heidelberg Pharma has over 116 employees. |
| Is Heidelberg Pharma publicly listed? | Yes, Heidelberg Pharma is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Heidelberg Pharma? | Heidelberg Pharma trades under HPHA ticker. |
| When did Heidelberg Pharma go public? | Heidelberg Pharma went public in 2006. |
| Who are competitors of Heidelberg Pharma? | Heidelberg Pharma main competitors are Alpha Cognition, Kotra Industries, vTv Therapeutics, Innate Pharma. |
| What is the current market cap of Heidelberg Pharma? | Heidelberg Pharma's current market cap is $151M. |
| What is the current revenue of Heidelberg Pharma? | Heidelberg Pharma's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of Heidelberg Pharma? | Current revenue multiple of Heidelberg Pharma is 77.8x. |
| Is Heidelberg Pharma profitable? | No, Heidelberg Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.